The agreements have a combined value of $5.9 million and these projects are expected to be substantially completed within a 15-month period. Telix is a biopharmaceutical company specializing
These therapeutic antibodies include ‘blood-brain barrier (BBB)’ penetrating bispecific antibodies (BsAb) (VEGF/undisclosed BBB target BsAb, undisclosed target/undisclosed BBB target BsAb); immune cell engaging bispecific antibodies (4-1BB/undisclosed target BsAb,
According to the American Heart Association, more than 900,000 people are diagnosed with heart failure every year in the United States. The condition, which results from the failure
The European Commission will review the CHMP recommendation and a final decision on the Marketing Authorisation Application for Cablivi in the European Union is expected in the coming
The companies announced that they had entered into exclusive talks on April 17, 2018. The signing of this Share Purchase Agreement marks a critical step on the way
Based on the results of this analysis, the DRC determined that the trial was futile, meaning that it was not likely to meet its primary end-point upon completion
The US biotechnology company had formed the JV in 2012 with Samsung BioLogics and has held a stake of around 5.4%. Samsung Bioepis is focused on advancing a pipeline
As part of the collaboration, a C-Trap optical tweezers–fluorescence microscope has been installed at the University of Cambridge and will be used by AstraZeneca, University of Cambridge research
Women with BRCA-mutated (BRCAm) advanced ovarian cancer treated 1st-line with Lynparza maintenance therapy had a statistically-significant and clinically-meaningful improvement in progression-free survival compared to placebo. The safety and tolerability
This deal builds on the VivaGel® BV licence signed with Mundipharma in May 2018 for Asia, the Middle East, Africa and parts of Latin America. Mundipharma is a
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.